SG10201805177PA - Use of ferric citrate in the treatment of chronic kidney disease patients - Google Patents
Use of ferric citrate in the treatment of chronic kidney disease patientsInfo
- Publication number
- SG10201805177PA SG10201805177PA SG10201805177PA SG10201805177PA SG10201805177PA SG 10201805177P A SG10201805177P A SG 10201805177PA SG 10201805177P A SG10201805177P A SG 10201805177PA SG 10201805177P A SG10201805177P A SG 10201805177PA SG 10201805177P A SG10201805177P A SG 10201805177PA
- Authority
- SG
- Singapore
- Prior art keywords
- increase
- iron
- kidney disease
- chronic kidney
- disease patients
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 3
- 229960002413 ferric citrate Drugs 0.000 title abstract 3
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 title abstract 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 8
- 229910052742 iron Inorganic materials 0.000 abstract 4
- 210000002966 serum Anatomy 0.000 abstract 3
- 239000003173 antianemic agent Substances 0.000 abstract 2
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- 102000008857 Ferritin Human genes 0.000 abstract 1
- 108050000784 Ferritin Proteins 0.000 abstract 1
- 238000008416 Ferritin Methods 0.000 abstract 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 206010022971 Iron Deficiencies Diseases 0.000 abstract 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662565P | 2012-06-21 | 2012-06-21 | |
| US201361757229P | 2013-01-28 | 2013-01-28 | |
| US201361801050P | 2013-03-15 | 2013-03-15 | |
| US201361800618P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201805177PA true SG10201805177PA (en) | 2018-07-30 |
Family
ID=49769729
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408521WA SG11201408521WA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
| SG10201805177PA SG10201805177PA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408521WA SG11201408521WA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20130345303A1 (de) |
| EP (3) | EP4335436A3 (de) |
| JP (4) | JP2015535209A (de) |
| KR (2) | KR102150135B1 (de) |
| CN (2) | CN104884055A (de) |
| AU (2) | AU2013278000A1 (de) |
| BR (1) | BR112014032049A2 (de) |
| CA (1) | CA2876982A1 (de) |
| DK (1) | DK3730136T3 (de) |
| EA (1) | EA201590062A1 (de) |
| ES (2) | ES2970050T3 (de) |
| HK (2) | HK1210013A1 (de) |
| IL (1) | IL236356A0 (de) |
| MX (1) | MX2014015615A (de) |
| PL (1) | PL3730136T3 (de) |
| SG (2) | SG11201408521WA (de) |
| WO (1) | WO2013192565A2 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012000892A (es) | 2009-07-21 | 2012-06-01 | Keryx Biopharmaceuticals Inc | Formas de dosificacion de citrato ferrico. |
| TWI653043B (zh) * | 2012-12-20 | 2019-03-11 | 瑞士商伊蘭科動物健康公司 | 新用途 |
| RU2728778C2 (ru) | 2013-06-05 | 2020-07-31 | Трисида, Инк. | Протон-связывающие полимеры для перорального введения |
| ES2856261T3 (es) * | 2013-10-01 | 2021-09-27 | Fresenius Medical Care Deutschland Gmbh | Método y aparatos para determinar una pérdida diaria de hierro de un paciente |
| EP3747432A1 (de) * | 2013-11-04 | 2020-12-09 | Keryx Biopharmaceuticals, Inc. | Eisenzitrat zur reduzierung von herzinsuffizienz bei patienten mit chronischer nierenkrankheit |
| WO2015110968A1 (en) * | 2014-01-23 | 2015-07-30 | Lupin Limited | Pharmaceutical grade ferric citrate and method for its production |
| WO2015198304A1 (en) | 2014-06-22 | 2015-12-30 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| JP6903576B2 (ja) | 2014-12-10 | 2021-07-14 | トリシダ・インコーポレイテッドＴｒｉｃｉｄａ， Ｉｎｃ． | 経口投与用プロトン結合ポリマー |
| AU2016226250B2 (en) * | 2015-03-04 | 2021-05-27 | Keryx Biopharmaceuticals, Inc. | Use of ferric citrate in the treatment of iron-deficiency anemia |
| CN104688706B (zh) * | 2015-04-01 | 2017-07-14 | 成都欣捷高新技术开发有限公司 | 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法 |
| WO2016162794A1 (en) * | 2015-04-08 | 2016-10-13 | Leiutis Pharmaceuticals Pvt Ltd | Pharmaceutical compositions of ferric citrate |
| WO2016162888A1 (en) * | 2015-04-09 | 2016-10-13 | Actavis Group Ptc Ehf. | Process for preparing pharmaceutical grade ferric citrate |
| MX2018013476A (es) | 2016-05-06 | 2019-03-28 | Tricida Inc | Composiciones para tratar trastornos acido-base. |
| EP3685831A4 (de) | 2017-09-19 | 2021-06-16 | Japan Tobacco Inc. | Verwendung von eisen(iii)citrat zur prävention und / oder behandlung von eisenmangel bei patientinnen mit hypermenorrhoe und/oder patientinnen mit einer hypermenorrhoe-assoziierten gynäkologischen erkrankung |
| CA3080651A1 (en) | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| WO2019236639A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| AU2019370677A1 (en) * | 2018-10-29 | 2021-05-27 | Pharmacosmos Holding A/S | Treating iron deficiency with ferric carboxymaltose |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| WO2022251563A1 (en) | 2021-05-27 | 2022-12-01 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
| CN115024495B (zh) * | 2022-06-27 | 2024-03-22 | 北京金康普食品科技有限公司 | 改善肾病患者钙磷代谢的营养组合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180094B1 (en) * | 1996-07-19 | 2001-01-30 | Nikken Chemicals Co., Ltd. | Remedies for hyperphosphatemia |
| US5753706A (en) * | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
| US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| TWI335218B (en) * | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| CN1600302A (zh) * | 2003-09-22 | 2005-03-30 | 宝龄富锦生技股份有限公司 | 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品 |
| US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
| NZ566743A (en) | 2005-08-18 | 2010-07-30 | Globoasia Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
| KR20080082674A (ko) * | 2006-01-06 | 2008-09-11 | 루이트폴드 파머수티컬스, 인코퍼레이티드 | 철을 투여하기 위한 방법 및 조성물 |
| WO2007089577A2 (en) | 2006-01-30 | 2007-08-09 | Globoasia, Llc | Method of reversing, preventing, delaying or stabilizing soft tissue calcification |
| MX2012000892A (es) | 2009-07-21 | 2012-06-01 | Keryx Biopharmaceuticals Inc | Formas de dosificacion de citrato ferrico. |
-
2013
- 2013-06-21 JP JP2015518623A patent/JP2015535209A/ja active Pending
- 2013-06-21 PL PL20163104.1T patent/PL3730136T3/pl unknown
- 2013-06-21 SG SG11201408521WA patent/SG11201408521WA/en unknown
- 2013-06-21 CN CN201380044271.0A patent/CN104884055A/zh active Pending
- 2013-06-21 CN CN202110644193.4A patent/CN113244209A/zh active Pending
- 2013-06-21 CA CA2876982A patent/CA2876982A1/en not_active Abandoned
- 2013-06-21 MX MX2014015615A patent/MX2014015615A/es unknown
- 2013-06-21 WO PCT/US2013/047134 patent/WO2013192565A2/en active Application Filing
- 2013-06-21 KR KR1020157001458A patent/KR102150135B1/ko active IP Right Grant
- 2013-06-21 KR KR1020207024260A patent/KR20200103855A/ko not_active IP Right Cessation
- 2013-06-21 EP EP23219273.2A patent/EP4335436A3/de active Pending
- 2013-06-21 ES ES20163104T patent/ES2970050T3/es active Active
- 2013-06-21 EA EA201590062A patent/EA201590062A1/ru unknown
- 2013-06-21 US US13/924,332 patent/US20130345303A1/en not_active Abandoned
- 2013-06-21 BR BR112014032049A patent/BR112014032049A2/pt not_active IP Right Cessation
- 2013-06-21 SG SG10201805177PA patent/SG10201805177PA/en unknown
- 2013-06-21 DK DK20163104.1T patent/DK3730136T3/da active
- 2013-06-21 AU AU2013278000A patent/AU2013278000A1/en not_active Abandoned
- 2013-06-21 ES ES13807102T patent/ES2796254T3/es active Active
- 2013-06-21 EP EP20163104.1A patent/EP3730136B1/de active Active
- 2013-06-21 EP EP13807102.2A patent/EP2863906B1/de active Active
-
2014
- 2014-04-25 US US14/262,465 patent/US20140234416A1/en not_active Abandoned
- 2014-10-24 US US14/523,656 patent/US20150079168A1/en not_active Abandoned
- 2014-12-18 IL IL236356A patent/IL236356A0/en unknown
-
2015
- 2015-10-28 HK HK15110673.6A patent/HK1210013A1/xx unknown
-
2016
- 2016-03-01 HK HK16102352.0A patent/HK1214503A1/zh unknown
-
2018
- 2018-04-10 JP JP2018075243A patent/JP2018138562A/ja active Pending
- 2018-05-08 AU AU2018203205A patent/AU2018203205B2/en not_active Ceased
-
2020
- 2020-02-25 JP JP2020029756A patent/JP2020100638A/ja active Pending
-
2022
- 2022-02-10 JP JP2022019167A patent/JP2022070945A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201805177PA (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
| MX2016005734A (es) | Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica. | |
| JO2828B1 (en) | Anti-Hepsidine antibodies and their uses | |
| WO2009125300A3 (en) | Oxygenation procedures for newborns and devices for use therein | |
| EA201071421A1 (ru) | Анти-flt3 антитела | |
| MY183637A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| SG158112A1 (en) | Hepatocyte growth factor (hgf) binding proteins | |
| NZ716473A (en) | Diagnosis and therapy of cancer involving cancer stem cells | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| MY165499A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| PH12015500084A1 (en) | Rspo3 binding agents and uses thereof | |
| IN2014MN02089A (de) | ||
| MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| PH12015501708A1 (en) | Methods of treating iron deficiency with soluble ferric pyrophosphate | |
| WO2010102216A3 (en) | Enhancing coagulation or reducing fibrinolysis | |
| MX2014002762A (es) | Uso de proteina c-met para predecir la eficacia de anticuerpos de factor de crecimiento de anti-hepatocitos (hgf) en pacientes con cancer esofagico y gastrico. | |
| WO2012075244A3 (en) | Use of hemoglobin effectors to increase the bioavailability of therapeutic gases | |
| MX2016003525A (es) | Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento. | |
| BR112014009414A2 (pt) | uso de micelas de proteína de soro do leite para melhorar o perfil de insulina em pacientes diabéti-cos | |
| BR112015028252A2 (pt) | método de tratamento de câncer de pulmão por vacinação com lipopeptídeo muc-1 | |
| WO2013142153A3 (en) | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics | |
| WO2014159917A3 (en) | Treatment for exposure to nerve agent | |
| ROUT | IRON DEFICIENCY ANEMIA | |
| BR112014029308A2 (pt) | um método de melhorar a função hepática |